Elite Pharmaceuticals, Inc.
ELTP
$0.53
$0.010.95%
OTC PK
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -9.67% | 25.67% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -9.67% | 25.67% | |||
| Cost of Revenue | 71.34% | -11.67% | |||
| Gross Profit | -48.31% | 57.42% | |||
| SG&A Expenses | 18.02% | 65.64% | |||
| Depreciation & Amortization | 0.00% | -3.66% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 51.84% | -3.78% | |||
| Operating Income | -62.15% | 70.10% | |||
| Income Before Tax | 2,880.98% | -102.93% | |||
| Income Tax Expenses | -62.64% | 133.95% | |||
| Earnings from Continuing Operations | 332.85% | -134.62% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 332.85% | -134.62% | |||
| EBIT | -62.15% | 70.10% | |||
| EBITDA | -61.04% | 67.80% | |||
| EPS Basic | 332.73% | -134.59% | |||
| Normalized Basic EPS | 3,133.33% | -102.46% | |||
| EPS Diluted | 154.00% | -162.89% | |||
| Normalized Diluted EPS | 2,966.67% | -102.46% | |||
| Average Basic Shares Outstanding | 0.33% | 0.00% | |||
| Average Diluted Shares Outstanding | 6.85% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||